RareResearch.AI
← Back to atlas

C505Y

Category 3/4 — Most DruggablePathogenicTransmembrane · predictedEditorial
CysteineTyrosine at position 505 · TM6 (496-516), helical transmembrane · WFS1 (Wolframin)

Cysteine → Tyrosine at position 505 inside wolframin's sixth transmembrane helix (TM6). ClinVar Pathogenic, associated with diabetes mellitus. AlphaMissense 0.892 (deep pathogenic range), DynaMut2 ΔΔG -0.81 kcal/mol (destabilising). A bilayer-embedded variant with a TM6-TM11 cross-helix mechanism.

Interactive 3D Structure

Wild-type reference
Wild-type C505 — hydrogen bond to V509
Fullscreen ↗
DynaMut2 mutant · C505Y
Mutant Y505 — hydrogen bond to Y508 lost (6 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

6 lost6 gained7 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondS502S502Preserved
Hydrogen bondY508Y508Preserved
Hydrogen bondV509V509Preserved
Hydrogen bondF886Lost
Polar contactT487Gained
Polar contactN500N500Preserved
Polar contactS502S502Preserved
Polar contactV503V503Preserved
Polar contactL507Lost
Polar contactY508Lost
Polar contactV509V509Preserved
Polar contactP885Gained
Van der WaalsN500Gained
Van der WaalsS502Lost
Van der WaalsL507Lost
Van der WaalsF886Lost
HydrophobicT487Gained
HydrophobicN500Gained
HydrophobicP885Gained

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.81kcal/mol
Destabilising — mild
AlphaMissense
0.892
LPath
AlphaFold pLDDT
82
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationPathogenic
Review statusno assertion criteria provided
Associated conditionsDiabetes mellitus
InheritanceDocumented in association with diabetes mellitus. The conservative substitution chemistry and bilayer location suggest the AD-leaning (Wolfram-like, DFNA6) presentation pattern.
Population frequency (gnomAD v4)Ultra-rare · AF 0.00034%
cDNA changec.1514G>A
ClinVar accessionVCV000918063
Last evaluated1/01/01 00:00

Observed at very low frequency in gnomAD.

Structural Context

Position 505 sits inside TM6, one of wolframin's eleven transmembrane helices. The AlphaFold model places C505 within 5 Å of PRO504 (2.5 Å), LEU506 (2.5 Å), SER502 (3.6 Å), PRO885 (4.1 Å), VAL503 (4.2 Å), and TYR508 (4.3 Å). The most structurally significant neighbor is PRO885 — that's a residue from TM11 (Atlas card P885L adjacent), positioned 4.1 Å away in the AlphaFold structure. This contact indicates that TM6 and TM11 cross each other in the membrane and pack against one another through the C505/P885 region.

The wild-type cysteine at position 505 is small and hydrophobic-character — its thiol can either remain free or, in oxidizing conditions, participate in disulfide formation. The local environment here is bilayer-embedded so disulfide formation is not the dominant mechanism. The wild-type's small volume fits cleanly into the TM6-TM11 packing interface.

Replacing cysteine with tyrosine here is unusually disruptive for two reasons. First, the volume increase: tyrosine's aromatic ring is roughly four times the side-chain mass of cysteine. The TM6-TM11 interface, which packs tightly through the C505/P885 region, cannot accommodate the larger side chain without significant rearrangement. Second, the introduced hydroxyl is unfavorable in the bilayer hydrophobic core — it would prefer to point toward the membrane-water interface, dragging the local geometry with it.

DynaMut2's |ΔΔG| of 0.81 kcal/mol captures the modest energetic cost of the fold absorbing this rearrangement. But the functional consequence — disrupted TM6-TM11 packing — is more severe than the ΔΔG alone suggests. AlphaMissense's 0.892 score reflects this. Compare with P504L (Atlas card adjacent): proline at position 504 plays a deliberate helix-kinking role, and removing it has its own structural cost. The two variants together — C505Y and P504L — characterize a vulnerable region in TM6 where multiple substitutions produce convergent functional disruption.

Amino-acid chemistry
Cysteine (C) → Tyrosine (Y) — a small thiol-bearing residue replaced by a large aromatic ring carrying a hydroxyl group. Loss of disulfide-bond capacity and a substantial volume increase, plus introduction of an H-bond donor/acceptor inside a hydrophobic membrane.
Position in the protein
TM6 (residues 496–516) · position 505 is bilayer-embedded. The hydrophobic membrane core penalizes the introduced tyrosine hydroxyl, which prefers polar or aqueous environments.

Druggability Assessment

Category 3/4 — Most Druggable. |ΔΔG| = 0.81 kcal/mol — fold survives. AlphaMissense 0.892 confirms deeply pathogenic signal.

The mechanism is disrupted TM6-TM11 helix-helix packing through the C505-P885 contact (4.1 Å in the AlphaFold model). The atlas-surfaced cross-helix interaction makes the therapeutic target geometric: a small molecule that stabilizes the TM6-TM11 interface, occupying the steric niche the wild-type cysteine maintained, would compensate.

The reciprocal Atlas card (P885L) shows the same interface from the TM11 side. Drug discovery targeting this interface has two converging mechanisms it could rescue simultaneously.

Why this matters

C505Y is one of the Atlas's clearest examples of cross-helix contact variants. The pathogenic mechanism is invisible without the AlphaFold-derived neighbor analysis: pre-atlas, C505 looked like a TM6 problem; with the atlas, it's a TM6-TM11 interface problem with a known reciprocal variant (P885L). Drug design at this interface gets reinforced from both sides.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the C505Y PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download C505Y PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Transmembrane496516 · Helical